501 W. 1ST Ave.
Columbus, OH 43215 USA
Corporation is dedicated to the advancement of essential bioavailability
enhancement and formulation development technology. ABITEC synthesizes and
produces lipid-based excipients to enhance bioavailability of poorly water-soluble
and poorly permeable molecules for the pharmaceutical industry.
has an expansive portfolio of CAPMUL® bioavailability enhancers,
which are medium-chain mono- and di-glycerides and propylene glycol esters.
These functional lipid excipients act as solubilizers and emulsifiers in oral,
topical, transdermal, and parenteral drug delivery systems. CAPMUL excipients
are recognized as the ideal starting point when formulating BCS Class II &
IV (poorly water soluble) and BCS Class III & IV (poorly permeable)
molecules. Lipid-based drug delivery systems may be formulated as liquid or
semi-solid formulations for oral dosage forms, as well as creams and ointments
for topical and transdermal applications.
CAPMUL may be used as a majority component in solubilization/emulsification
formulations. Or whenever necessary, CAPMUL-based formulations may be
customized with the inclusion of CAPTEX® medium-chain triglycerides
and/or ACCONON® non-ionic
surfactants, added for enhanced bioavailability.
introduces its new INJECTATM parenteral-grade lipid excipients to
enable improved solubilization and permeation for injectable APIs. The INJECTA-grade
portfolio of products launched include: Captex medium-chain tri-glycerides and
Capmul mono-and di-glycerides of glycol esters fully analyzed and packaged for
manufactures high-quality lipid excipients for drug delivery applications in
accordance with strict cGMP and applicable IPEC (International Pharmaceutical
Excipient Council) guidelines in ISO-certified facilities. ABITEC’s
customer-preferred portfolio of pharmaceutical excipients are monograph
compliant, supported by drug master files (DMFs), and have precedence of
use. For more information about all of
ABITEC’s invaluable solutions please contact us directly or visit our website.
latest updates follow us! Twitter LinkedIn
This record has been viewed 454